Publication:
The impact of tibolone and hormone therapy on serum C-reactive protein, tumor necrosis factor- and hepatocyte growth factor in postmenopausal women

Simple item page
dc.contributor.authorYOLDEMİR, AHMET TEVFİK
dc.contributor.authorsOezer, K. Sezer; Erenus, M.; Yoldemir, T.
dc.date.accessioned2022-03-12T17:36:34Z
dc.date.available2022-03-12T17:36:34Z
dc.date.issued2009
dc.description.abstractObjective To investigate the effect of tibolone and hormone treatment on serum C-reactive protein, tumor necrosis factor- and hepatocyte growth factor as independent markers of cardiovascular disease. Design Ninety-five normotensive and healthy postmenopausal women with no systemic or cardiac disease who attended the Marmara University Menopause Outpatient Clinic were included in this study. The women were assigned into three groups. The women who accepted hormone replacement therapy were randomized to two groups. Group 1 received 0.625mg conjugated estrogen (CE)+2.5mg medroxyprogesterone acetate (MPA)/day. Group 2 received 2.5mg tibolone/day. Group 3 was the control group consisting of women who did not want hormone replacement therapy. Serum samples were measured for highly specific C-reactive protein, tumor necrosis factor and hepatocyte growth factor before the treatment and after 6 months of therapy. Values at the end of the 6th month and baseline were compared. Results The increase in C-reactive protein and the decrease in tumor necrosis factor- levels demonstrated at the end of treatment were statistically significant, in both the hormone therapy and tibolone groups. However, the decrease in hepatocyte growth factor was significant only in the tibolone group. Conclusions The positive impact of both tibolone and hormone therapy on inflammatory markers appears to be protective against cardiovascular diseases. However, the clinical implications of these findings are yet to be evaluated in large clinical trials.
dc.identifier.doi10.1080/13697130802479580
dc.identifier.eissn1473-0804
dc.identifier.issn1369-7137
dc.identifier.urihttps://hdl.handle.net/11424/229284
dc.identifier.wosWOS:000262107400008
dc.language.isoeng
dc.publisherTAYLOR & FRANCIS LTD
dc.relation.ispartofCLIMACTERIC
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectTibolone
dc.subjectHormone Treatment
dc.subjectInflammatory Markers
dc.subjectESTROGEN PLUS PROGESTIN
dc.subjectREPLACEMENT THERAPY
dc.subjectCARDIOVASCULAR-DISEASE
dc.subjectINFLAMMATORY MARKERS
dc.subjectHEART-DISEASE
dc.subjectFACTOR-ALPHA
dc.subjectRISK
dc.subject17-BETA-ESTRADIOL
dc.subjectINTERLEUKIN-6
dc.subjectELEVATION
dc.titleThe impact of tibolone and hormone therapy on serum C-reactive protein, tumor necrosis factor- and hepatocyte growth factor in postmenopausal women
dc.typearticle
dspace.entity.typePublication
local.avesis.id7f8c4cf5-b63d-403a-9a64-b738e8947c48
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.articlenumberPII 905527241
local.journal.numberofpages6
oaire.citation.endPage71
oaire.citation.issue1
oaire.citation.startPage66
oaire.citation.titleCLIMACTERIC
oaire.citation.volume12
relation.isAuthorOfPublicationa83f8663-e08c-4cde-a28b-fbd444a689e0
relation.isAuthorOfPublication.latestForDiscoverya83f8663-e08c-4cde-a28b-fbd444a689e0

Files

Collections

Research Outputs